Acurx Pharma receives Nasdaq notice for non-compliance with equity requirement

Acurx Pharmaceuticals, Inc.

Notice based on 10-K for FY 2024; stockholders' equity fell below $2.5M minimum.
Company has 45 days (until May 9, 2025) to submit a Compliance Plan to Nasdaq.
If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.
If plan rejected, common stock subject to delisting; company can appeal to Hearing Panel.
Company cautions no assurance that plan will be accepted or compliance regained.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.